Cautious. TRAX scores 49/100, reflecting mixed signals: Leadership Alignment (45/100) suggests modest founder commitment or dilution concerns that warrant scrutiny, while a neutral Vulnerability Index offers no clear moat or structural headwind. Without compelling growth or margin expansion data, the risk-reward lacks conviction.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for First Tracks Biotherapeutics, I:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 49/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates First Tracks Biotherapeutics, I (TRAX) at 49/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. TRAX scores 49/100, reflecting mixed signals: Leadership Alignment (45/100) suggests modest founder commitment or dilution concerns that warrant scrutiny, while a neutral Vulnerability Index offers no clear moat or structural head
TRAX's current Stocky Verdict is 49/100, placing it in the "Cautious" band. This composite combines a 50/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for First Tracks Biotherapeutics, I yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
First Tracks Biotherapeutics, I scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
First Tracks Biotherapeutics, I's Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to First Tracks Biotherapeutics, I.
Sign up free and unlock the full analysis on TRAX — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for TRAX in the app.
